mk-8825 and Migraine-Disorders

mk-8825 has been researched along with Migraine-Disorders* in 3 studies

Other Studies

3 other study(ies) available for mk-8825 and Migraine-Disorders

ArticleYear
Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia.
    Cephalalgia : an international journal of headache, 2014, Volume: 34, Issue:8

    The release of calcitonin gene-related peptide (CGRP) from trigeminal nerves plays a central role in the pathophysiology of migraine and clinical evidence shows an antimigraine effect for CGRP receptor antagonists. Systemic administration of nitroglycerin (NTG), a nitrovasodilator, consistently provokes spontaneous-like migraine attacks in migraine sufferers; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission.. The aim of this article is to test the analgesic effect of the CGRP receptor antagonist MK-8825 in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia.. MK-8825 showed analgesic activity when administered alone at both the tail flick test and the formalin test. Furthermore, the CGRP antagonist proved effective in counteracting NTG-induced hyperalgesia in both tests. MK-8825 indeed reduced the nociceptive behavior when administered either simultaneously or prior to (30-60 minutes before) NTG.. These data suggest that MK-8825 may represent a potential therapeutic tool for the treatment of migraine.

    Topics: Animals; Calcitonin Gene-Related Peptide Receptor Antagonists; Disease Models, Animal; Hyperalgesia; Male; Migraine Disorders; Nitroglycerin; Nociceptors; Pain Threshold; Pyridines; Rats; Rats, Sprague-Dawley; Reaction Time; Spiro Compounds

2014
The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion.
    The journal of headache and pain, 2013, Nov-20, Volume: 14

    Calcitonin gene-related peptide (CGRP) and nitric oxide (NO) are regarded as key mediators in migraine and other primary headaches. Migraineurs respond to infusion of nitroglycerin with delayed headaches, and inhibition of CGRP receptors has been shown to be effective in migraine therapy. In animal experiments nitrovasodilators like nitroglycerin induced increases in spinal trigeminal activity, which were reversed after inhibition of CGRP receptors. In the present study we asked if CGRP receptor inhibition can also prevent spinal trigeminal activity induced by nitroglycerin.. In isoflurane anaesthetised rats extracellular recordings were made from neurons in the spinal trigeminal nucleus with meningeal afferent input. The non-peptide CGRP receptor inhibitor MK-8825 (5 mg/kg) dissolved in acidic saline (pH 3.3) was slowly infused into rats one hour prior to prolonged glyceryl trinitrate (nitroglycerin) infusion (250 μg/kg/h for two hours).. After infusion of MK-8825 the activity of spinal trigeminal neurons with meningeal afferent input did not increase under continuous nitroglycerin infusion but decreased two hours later below baseline. In contrast, vehicle infusion followed by nitroglycerin was accompanied by a transient increase in activity.. CGRP receptors may be important in an early phase of nitroglycerin-induced central trigeminal activity. This finding may be relevant for nitroglycerin-induced headaches.

    Topics: Animals; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Male; Migraine Disorders; Neurons; Nitric Oxide; Nitroglycerin; Pyridines; Rats; Rats, Wistar; Spiro Compounds; Trigeminal Nucleus, Spinal

2013
MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.
    Bioorganic & medicinal chemistry letters, 2012, Jun-15, Volume: 22, Issue:12

    Rational modification of the clinically tested CGRP receptor antagonist MK-3207 (3) afforded an analogue with increased unbound fraction in rat plasma and enhanced aqueous solubility, 2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(6S)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-3-yl]acetamide (MK-8825) (6). Compound 6 maintained similar affinity to 3 at the human and rat CGRP receptors but possessed significantly improved in vivo potency in a rat pharmacodynamic model. The overall profile of 6 indicates it should find utility as a rat tool to investigate effects of CGRP receptor blockade in vivo.

    Topics: Administration, Oral; Analgesics; Animals; Biological Availability; Calcitonin Gene-Related Peptide Receptor Antagonists; Disease Models, Animal; Dogs; Humans; Macaca mulatta; Mice; Migraine Disorders; Pyridines; Rats; Receptors, Calcitonin Gene-Related Peptide; Species Specificity; Spiro Compounds

2012